AETERNA ZENTARIS INC (AEZS) Stock Price, Forecast & Analysis
USA - NASDAQ:AEZS - CA0079756007 - Common Stock
AEZS Key Statistics, Chart & Performance
The current stock price of AEZS is 5.72 USD. In the past month the price decreased by -16.86%. In the past year, price decreased by -51.69%.
AEZS Latest News, Press Relases and Analysis
AEZS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About AEZS
Company Profile
Aeterna Zentaris Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The firm is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The firm's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources, which are used in cosmeceutical products, such as oat beta glucan and avenanthramides, and is being developed as potential nutraceuticals and/or pharmaceuticals. Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-1.
Company Info
AETERNA ZENTARIS INC
C/O Norton Rose Fulbright Canada Llp, 222 Bay Street, Suite 3000, Po Box 53
TORONTO ONTARIO 29486 CA
CEO: Paulini Klaus
Employees: 21
Phone: 18439003201
AETERNA ZENTARIS INC / AEZS FAQ
What does AEZS do?
Aeterna Zentaris Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The firm is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The firm's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources, which are used in cosmeceutical products, such as oat beta glucan and avenanthramides, and is being developed as potential nutraceuticals and/or pharmaceuticals. Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-1.
What is the current price of AEZS stock?
The current stock price of AEZS is 5.72 USD. The price increased by 5.93% in the last trading session.
What is the dividend status of AETERNA ZENTARIS INC?
AEZS does not pay a dividend.
How is the ChartMill rating for AETERNA ZENTARIS INC?
AEZS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is AETERNA ZENTARIS INC (AEZS) stock traded?
AEZS stock is listed on the Nasdaq exchange.
Can you provide the upcoming earnings date for AETERNA ZENTARIS INC?
AETERNA ZENTARIS INC (AEZS) will report earnings on 2024-11-07, before the market open.
AEZS Technical Analysis
AEZS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AEZS. AEZS has a bad profitability rating. Also its financial health evaluation is rather negative.
AEZS Financial Highlights
Over the last trailing twelve months AEZS reported a non-GAAP Earnings per Share(EPS) of -11. The EPS decreased by -274.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.8% | ||
| ROE | -139.22% | ||
| Debt/Equity | 0.01 |
AEZS Forecast & Estimates
For the next year, analysts expect an EPS growth of 68.75% and a revenue growth -2.27% for AEZS